NTRK1 and lung carcinoma: In addition, a recent presentation at the American Society of Clinical Oncology demonstrated that larotrectinib, a small-molecule pan-TRK inhibitor, was associated with durable antitumor activity in patients with TRK fusions and a wide variety of malignancies, including lung cancer [16].